^
BIOMARKER:
PIK3CA H1047R
i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Entrez ID:
Related biomarkers:
PIK3CA H1047R
CRC
cetuximab
Resistant
:
C3
PIK3CA H1047R
HER2 Positive Breast Cancer
PF-05212384 + Herzuma (trastuzumab biosimilar)
Sensitive
:
C3
PIK3CA H1047R
NSCLC
trametinib + dabrafenib
Sensitive
:
C3
PIK3CA H1047R
Breast Cancer
TAS-117
Sensitive
:
C3
PIK3CA H1047R
Melanoma
dabrafenib
Sensitive
:
C4
PIK3CA H1047R
HER2 Positive Breast Cancer
everolimus
Sensitive
:
C4
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + everolimus
Sensitive
:
C4
PIK3CA H1047R
Salivary Gland Cancer
vandetanib
Sensitive
:
C4
PIK3CA H1047R
Colon Cancer
PF-05212384
Sensitive
:
D
PIK3CA H1047R
SCCHN
trametinib
Sensitive
:
D
PIK3CA H1047R
Endometrial Cancer
MEN1611
Sensitive
:
D
PIK3CA H1047R
CRC
MEN1611
Sensitive
:
D
PIK3CA H1047R
Breast Cancer
trastuzumab + lapatinib
Resistant
:
D
PIK3CA H1047R
Breast Cancer
trastuzumab + MEN1611
Sensitive
:
D
PIK3CA H1047R
Breast Cancer
GDC-0941
Sensitive
:
D
PIK3CA H1047R
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive
:
D
PIK3CA H1047R
Head and Neck Cancer
alpelisib
Sensitive
:
D
PIK3CA H1047R
Ovarian Cancer
MEN1611
Sensitive
:
D
PIK3CA H1047R
Ovarian Cancer
LX-086
Sensitive
:
D
PIK3CA H1047R
Head and Neck Cancer
SHR-A1307
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive
:
D
PIK3CA H1047R
HER2 Negative Breast Cancer
LX-086
Sensitive
:
D
PIK3CA H1047R
SCCHN
GDC-0941
Resistant
:
D
PIK3CA H1047R
SCCHN
BMS-722782
Resistant
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our